Overview

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

Status:
Completed

Trial end date:
2004-10-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine if Provigil® (modafinil) at a dose of 200 mg once daily is safe and effective for treating symptoms of sleepiness and fatigue associated with Major Depressive Disorder when added to a SSRI.

Phase:

Phase 4

Details

Lead Sponsor:

Emory University

Collaborator:

Cephalon

Treatments:

Armodafinil
Modafinil